HARPOON THERAPEUTICS INC (HARP) Stock Price, Quote, News and Overview
NASDAQ:HARP - Nasdaq - US41358P2056 - Common Stock - Currency: USD
HARP Quote, Performance and Key Statistics
23.01
+0.02 (+0.09%)
The current stock price of HARP is 23.01 USD. In the past month the price increased by 3%. In the past year, price increased by 248.64%.
HARP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About HARP
Company Profile
Harpoon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2019-02-08. Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The firm is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
Company Info
HARPOON THERAPEUTICS INC
611 Gateway Boulevard, Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Gerald McMahon
Employees: 53
Company Website: https://www.harpoontx.com/
Phone: 16504437400
HARPOON THERAPEUTICS INC / HARP FAQ
What is the stock price of HARPOON THERAPEUTICS INC today?
The current stock price of HARP is 23.01 USD. The price increased by 0.09% in the last trading session.
What is the ticker symbol for HARPOON THERAPEUTICS INC stock?
The exchange symbol of HARPOON THERAPEUTICS INC is HARP and it is listed on the Nasdaq exchange.
On which exchange is HARP stock listed?
HARP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HARPOON THERAPEUTICS INC stock?
15 analysts have analysed HARP and the average price target is 24.14 USD. This implies a price increase of 4.93% is expected in the next year compared to the current price of 23.01. Check the HARPOON THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HARPOON THERAPEUTICS INC worth?
HARPOON THERAPEUTICS INC (HARP) has a market capitalization of 492.41M USD. This makes HARP a Small Cap stock.
How many employees does HARPOON THERAPEUTICS INC have?
HARPOON THERAPEUTICS INC (HARP) currently has 53 employees.
What are the support and resistance levels for HARPOON THERAPEUTICS INC (HARP) stock?
HARPOON THERAPEUTICS INC (HARP) has a support level at 22.34 and a resistance level at 23.02. Check the full technical report for a detailed analysis of HARP support and resistance levels.
Is HARPOON THERAPEUTICS INC (HARP) expected to grow?
The Revenue of HARPOON THERAPEUTICS INC (HARP) is expected to grow by 8.24% in the next year. Check the estimates tab for more information on the HARP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HARPOON THERAPEUTICS INC (HARP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HARP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HARP, evaluating the profitability, health, valuation and growth aspects
- HARPOON THERAPEUTICS INC (HARP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HARPOON THERAPEUTICS INC (HARP) Sales and EPS estimates to see what analysts future expectations are.
- HARPOON THERAPEUTICS INC (HARP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HARPOON THERAPEUTICS INC (HARP) Insider and Institutional Ownership to learn about the owners and their transactions.
- HARPOON THERAPEUTICS INC (HARP) Stock Chart to make your own analysis
- HARPOON THERAPEUTICS INC (HARP) Latest news and press-releases to stay up to date.
Does HARPOON THERAPEUTICS INC (HARP) stock pay dividends?
HARP does not pay a dividend.
When does HARPOON THERAPEUTICS INC (HARP) report earnings?
HARPOON THERAPEUTICS INC (HARP) will report earnings on 2024-03-25, after the market close.
What is the Price/Earnings (PE) ratio of HARPOON THERAPEUTICS INC (HARP)?
HARPOON THERAPEUTICS INC (HARP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.76).
HARP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HARP. When comparing the yearly performance of all stocks, HARP is one of the better performing stocks in the market, outperforming 99.07% of all stocks.
HARP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HARP. HARP may be in some trouble as it scores bad on both profitability and health.
HARP Financial Highlights
Over the last trailing twelve months HARP reported a non-GAAP Earnings per Share(EPS) of -8.76. The EPS increased by 44.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.08% | ||
| ROE | -677.78% | ||
| Debt/Equity | 1.96 |
HARP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to HARP. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 90.06% and a revenue growth 8.24% for HARP